Ann: Quarterly Activity Report & Appendix 4C, page-6

Agreed, though a bit of an uptick in revenues on the corresponding Quarter last year would not be unreasonable to expect.

BioHOrizons starting sales in the UK this quarter at least. Hopefully that and the sales inertia kicks in.

Not a particularly enthralling quarterly. Next catalyst ATI vs Surgery 12 month data likely June if last patient May 2022.

At the risk of boring others, I implore investors to read the Veritas report I posted yesterday, if you have not, and get this around to other investors. It repeats much of what you know and what we have discussed on here, but its comprehensive and professional on OCC's prospects:

https://mcusercontent.com/418010b734f74e4d79ccacb45/files/f36818c1-6b34-8cb8-bbe2-38a0f2a6c03b/OCC_180423.pdf

(and rightly modest on expectations of speed of execution of OCC management it appears!)